SCHEMBL10085577

SCHEMBL10085577

COC(=O)Cn1c(C)nc2ccc(C)cc2c1=O

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 5/20 0.51
▸ ALDH1A1 P00352 4/20 0.51
▸ KMT2A Q03164 3/20 0.51
▸ HPGD P15428 2/20 0.51
▸ HSD17B10 Q99714 2/20 0.51
▸ MEN1 O00255 2/20 0.51
▸ MAPT P10636 1/20 0.51
▸ AKR1B10 O60218 1/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ POLB P06746 2/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.46
▸ HDAC3 O15379 1/20 0.46
▸ HDAC4 P56524 1/20 0.46
▸ HDAC1 Q13547 1/20 0.46
▸ HDAC7 Q8WUI4 1/20 0.46
▸ HDAC2 Q92769 1/20 0.46
▸ HDAC10 Q969S8 1/20 0.46
▸ HDAC11 Q96DB2 1/20 0.46
▸ HDAC8 Q9BY41 1/20 0.46
▸ HDAC6 Q9UBN7 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10085580 0.86 AKR1B10 (0.60) KDM4EALDH1A1KMT2AHPGDHSD17B10
SCHEMBL10084700 0.76 POLB (0.51) KDM4EALDH1A1KMT2AHPGDHSD17B10
SCHEMBL9245910 0.76 POLB (0.45) KDM4EALDH1A1KMT2AHPGDHSD17B10
SCHEMBL13319144 0.76 POLB (0.54) KDM4EALDH1A1KMT2AHSD17B10MEN1
SCHEMBL31751270 0.75 KDM4E (0.47) KDM4EALDH1A1KMT2AHPGDHSD17B10
SCHEMBL10085584 0.74 HSD17B10 (0.53) KDM4EALDH1A1KMT2AHSD17B10MEN1
SCHEMBL10084475 0.74 HSD17B10 (0.47) KDM4EALDH1A1KMT2AHPGDHSD17B10
SCHEMBL28594238 0.73 KDM4E (0.67) KDM4EALDH1A1KMT2AHPGDHSD17B10
SCHEMBL10085579 0.72 HSD17B10 (0.54) KDM4EALDH1A1KMT2AHSD17B10MEN1
SCHEMBL13409638 0.71 POLB (0.71) KDM4EALDH1A1KMT2AHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590975-B1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2015-08-19 — — EP disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
US-8859544-B2 Indolizine derivatives, process for the preparation thereof and therapeutic use thereof SANOFI (FR) 2014-10-14 — — US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-05-09 — — US disclosed
WO-2012004731-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2012-01-12 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130116249-A1 INDOLIZINE DERIVATIVES, PROCESS FOR THE PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CCNY, INMT, IDO1 KDM4E 633/4885ALDH1A1 3536/4885KMT2A 1538/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback